The Brokerages Set United Therapeutics Corp. (UTHR) Target Price at $146.75

The Brokerages Set United Therapeutics Corp. (UTHR) Target Price at $146.75

United Therapeutics Corp. (NASDAQ:UTHR) has been assigned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the company. Eight research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $146.75.

Several brokerages have issued reports on UTHR. Zacks Investment Research cut shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating in a report on Monday, August 1st. JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating on the stock in a report on Friday, July 29th. Jefferies Group reiterated a “hold” rating and set a $120.00 target price on shares of United Therapeutics Corp. in a report on Friday, July 29th. HC Wainwright reiterated a “hold” rating on shares of United Therapeutics Corp. in a report on Friday, July 29th. Finally, Wedbush reiterated an “outperform” rating and set a $229.00 target price on shares of United Therapeutics Corp. in a report on Thursday, July 28th.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 116.89 on Monday. The company has a market capitalization of $5.08 billion, a price-to-earnings ratio of 5.65 and a beta of 1.42. The stock has a 50 day moving average of $121.73 and a 200-day moving average of $116.02. United Therapeutics Corp. has a 52 week low of $97.52 and a 52 week high of $164.04.

United Therapeutics Corp. (NASDAQ:UTHR) last posted its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, topping the Zacks’ consensus estimate of $3.22 by $1.33. The firm had revenue of $412.60 million for the quarter, compared to analysts’ expectations of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The business’s revenue for the quarter was up 18.8% on a year-over-year basis. During the same period in the prior year, the business posted $2.55 earnings per share. On average, analysts anticipate that United Therapeutics Corp. will post $15.82 EPS for the current year.

In other news, CEO Martine A. Rothblatt sold 1,271 shares of the firm’s stock in a transaction that occurred on Thursday, July 28th. The shares were sold at an average price of $117.05, for a total transaction of $148,770.55. Following the sale, the chief executive officer now owns 1,411 shares of the company’s stock, valued at approximately $165,157.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,284 shares of the firm’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $112.77, for a total transaction of $144,796.68. Following the sale, the chief executive officer now directly owns 1,424 shares in the company, valued at approximately $160,584.48. The disclosure for this sale can be found here. 7.50% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of UTHR. Scopia Capital Management LP boosted its stake in shares of United Therapeutics Corp. by 48.1% in the first quarter. Scopia Capital Management LP now owns 4,219,281 shares of the biotechnology company’s stock worth $470,154,000 after buying an additional 1,370,698 shares during the last quarter. Emerald Acquisition Ltd. purchased a new stake in shares of United Therapeutics Corp. during the second quarter worth approximately $47,352,000. Thompson Siegel & Walmsley LLC boosted its stake in shares of United Therapeutics Corp. by 140.3% in the second quarter. Thompson Siegel & Walmsley LLC now owns 567,786 shares of the biotechnology company’s stock worth $60,140,000 after buying an additional 331,476 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of United Therapeutics Corp. by 21.2% in the second quarter. AQR Capital Management LLC now owns 1,584,113 shares of the biotechnology company’s stock worth $167,790,000 after buying an additional 277,266 shares during the last quarter. Finally, AJO LP boosted its stake in shares of United Therapeutics Corp. by 13.8% in the second quarter. AJO LP now owns 2,141,541 shares of the biotechnology company’s stock worth $226,832,000 after buying an additional 258,931 shares during the last quarter.

Related posts

Leave a Comment